The long term treatment with B-carotene in erythropoietic protoporphyria: a controlled trial

Corbett, Mandy; Herxheimer, Andrew; Magnus, I.A.; Ramsay, Colin A.; Kobza-Black, A.

doi:10.1111/j.1365-2133.1977.tb14273.x

Cited by 79 publications

(31 citation statements)

References 7 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of the painful photosensitivity, mediated by the excess of protoporphyrin IX, is difficult. β‐carotene was found to be no more effective than placebo in a randomized controlled trial (RCT), and in practice, few patients with EPP find the treatment worthwhile . NB‐UVB has yet to be assessed formally in the treatment of EPP (or XLDPP), although anecdotal evidence suggests that it may be of benefit .…”

Section: Reportmentioning

confidence: 99%

X-linked dominant protoporphyria: a new porphyria

Seager

Whatley

Anstey

et al. 2014

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

X-linked dominant protoporphyria (XLDPP) was first reported in the genetics literature in 2008. It has a phenotype very similar to erythropoietic protoporphyria (EPP), but is distinguished from EPP by higher concentrations of erythrocyte protoporphyrin (of which a high proportion is zinc-chelated), its apparently higher incidence of liver disease, and an X-linked dominant pattern of inheritance. Dermatologists should understand how XLDPP differs from EPP, in order to advise newly diagnosed patients correctly about the genetic implications and the long-term management strategy. We present a case series of XLDPP to introduce this condition to the dermatology literature.

show abstract

Section: Reportmentioning

confidence: 99%

X-linked dominant protoporphyria: a new porphyria

Seager

Whatley

Anstey

et al. 2014

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Increase of UV tolerance was seen in 84% of 133 patients taking betacarotene with a starting dose of 15 mg/day to 180 mg/day [27]. Whereas in a controlled, cross-over trial in 14 patients suffering from erythropoietic protoporphyria no significant difference was found between betacarotene (100 mg/day) and placebo [28].…”

Section: Betacarotenementioning

confidence: 92%

Relevance of Oral Supplementation with Antioxidants for Prevention and Treatment of Skin Disorders

Tebbe

2001

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Reactive oxygen species can cause harmful effects in keratinocytes and fibroblasts if antioxidative defence mechanisms are exhausted. Therefore, it seems to be reasonable to prove if oral supplementation with various nutrient antioxidants is useful in prevention or treatment of skin disorders especially in those mediated by UV irradiation. Betacarotene, ascorbic acid and tocopherol have been tested alone or in combination for prevention of sunburn, photodermatoses and photocarcinogenesis with divergent results. Other candidates for oral antioxidative supplementation in humans are selenium and polyphenols. However, clinical data are limited or missing up to date.

show abstract

“…However, another study on 23 healthy volunteers showed no statistically significant carotenoid‐dependent photoprotection against UVA‐, UVB‐ or PUVA‐induced erythema, and also no decrease in UVB‐induced DNA damage 28 . The only controlled trial of β‐carotene in the treatment of EPP showed no significant improvement over placebo 29 but this study was subsequently criticised for possible under‐dosage with β‐carotene. This was unfortunate, as high‐dose β‐carotene has been demonstrated to be safe and well‐tolerated 30 .…”

Section: Treatment Of Photosensitivitymentioning

confidence: 95%

Systemic photoprotection with α-tocopherol (vitamin E) and β-carotene

Anstey

2002

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Cutaneous photodamage is partly mediated via oxidative pathways and there is evidence to suggest that antioxidants within the skin may have a photoprotective effect. Antioxidant activity is provided by a number of naturally occurring substances including alpha-tocopherol (vitamin E) and beta-carotene, whose effects are mediated by their capacity to quench singlet oxygen, scavenge free radicals and prevent the formation of free radicals. Beta-carotene has been used as treatment for various photosensitivity disorders for more than 30 years. The main indication for its use is in the treatment of the photosensitivity associated with erythropoietic protoporphyria. A role for beta-carotene in the prevention of non-melanoma skin cancer has yet to be demonstrated despite clinical research activity in this area. The role for alpha-tocopherol as a photoprotective agent is less clear-cut and it has yet to be established as treatment either for conditions characterized by photosensitivity or as an agent for preventing chronic photodamage or cutaneous malignancy.

show abstract

The long term treatment with B-carotene in erythropoietic protoporphyria: a controlled trial

Cited by 79 publications

References 7 publications

X-linked dominant protoporphyria: a new porphyria

X-linked dominant protoporphyria: a new porphyria

Relevance of Oral Supplementation with Antioxidants for Prevention and Treatment of Skin Disorders

Systemic photoprotection with α-tocopherol (vitamin E) and β-carotene

Contact Info

Product

Resources

About